TransCode Therapeutics, Inc. (BOATS:RNAZ) Financings

TransCode Therapeutics, Inc.

Financings

RaiseDate
Strategic investment of non-voting Series B convertible preferred stock
Announced: US$25M · Tungsten Advisors
Dealers: Tungsten Advisors (lead)
Buyers: CK Life Sciences Int'l., (Holdings) Inc. (subsidiary) (223.7337 shares of Series B Preferred Stock for $25 million; approximately 91% fully diluted together with the acquisition)
Use of proceeds: Primarily to advance clinical development of lead microRNA asset TTX-MC138 into a Phase 2 clinical trial
Oct 9, 2025
Registered direct offering of shares of common stock and warrants
Closed: US$10M raised · US$0.98 a share · Warrants at US$0.86 for 60 months · ThinkEquity
Dealers: ThinkEquity (lead)
Use of proceeds: Product development, including clinical trials of TTX-MC138 and IND-enabling studies, plus working capital and general corporate purposes
Mar 25, 2025
Private placement of shares of common stock with Series C and Series D warrants
Update: about US$8M · US$0.377 a share · Warrants at US$0.475 for 60 months · The Benchmark Company, LLC
Dealers: The Benchmark Company, LLC (lead)
Use of proceeds: General corporate purposes and working capital
Feb 25, 2025

Read by 6ix AI from the company's releases